Theraclion: Sonovein SpeedPulse Prototype Completes Varicose Vein Procedures in Under 30 Minutes
Theraclion presented the preliminary results of its Sonovein SpeedPulse prototype at the international congress of the Phlebology Days in Parma, held on May 22 and 23, 2026. This enhanced version of its focused ultrasound varicose vein treatment platform is currently in clinical evaluation and has demonstrated a significant reduction in procedure time.
Promising Initial Results from SpeedPulse
Theraclion announced the preliminary results of the SpeedPulse study, conducted in the Czech Republic by Professor Jaroslav Strejček. This study evaluates a prototype incorporating technological advancements in acoustics and robotics, designed to significantly accelerate treatment duration and simplify its use. Early observations indicate a major reduction in procedure time, with interventions now completed in under 30 minutes.
The improvements include enhanced ergonomics for physicians, made possible by an increased range of robotic movement and additional degrees of freedom. These advancements address a key challenge for adoption: making the treatment faster, simpler, and easier to integrate into daily practice.
Confirmed Interest from the Scientific Community
The international congress of the Phlebology Days held in Parma on May 22 and 23, 2026, confirmed the growing interest of the phlebological community in the Sonovein technology. Professor Strejček commented: 'The speed improvements observed with this new prototype are very impressive. We are seeing treatments performed much more quickly and consistently than before, while maintaining the benefits of a completely non-invasive approach.'
During the event, 13 Sonovein users and opinion leaders shared results from regular clinical practice, covering hundreds of patients, various types of veins, and several years of follow-up. Over a hundred healthcare professionals visited Theraclion's booth, marking the increasing commitment of the scientific community to the potential of non-invasive HIFU treatment.
Prospects for Improvement through Artificial Intelligence
Martin Deterre, CEO of Theraclion, stated: 'This ongoing work on artificial intelligence should allow us to go even further, reducing treatment times and improving the ergonomics of the device. We are eager to continue the next stages of development, validation, and industrialization in order to make these new features available to our users in the coming years.'
Theraclion emphasizes that the current prototype remains in clinical evaluation and is not yet commercialized. Additional development work and regulatory approvals will be necessary before any potential market introduction.
